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ABSTRACT 
OBJECTIVE: The Objective of this selective EBM review is to determine where or not, “Is 
Incidence of Nausea Influenced by Brintellix (Vortioxetine) in Patients over the Age of 18 with 
Major Depressive Disorder (MDD)?” 
STUDY DESIGN: Review of three English language primary studies, published between 2011 
and 2013 
DATA SOUCES: Three double blind randomized controlled trials (RCTs).  Sources were found 
on PubMed and Cochrane Library databases. 
 
OUTCOMES MEASURED: To measure the incidence of nausea in patients over 18 who are 
diagnosed with major depressive disorder taking Brintellix compared to a placebo.  
 
RESULTS:  The randomized controlled studies results found that Brintellix was found to 
increase incidence of nausea when compared to placebo. 
 
CONCLUSION: Brintellix treatment was well tolerated in patients 18 years and older with major 
depressive disorder; with nausea being the most common adverse event reported from patients. 
 
KEY WORDS: Brintellix, nausea, major depressive disorder 
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Introduction 
 Major Depressive Disorders (MDD) is a serious condition that may manifest itself in a 
variety of ways.  According to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-
5),  MDD is characterized by five or more symptoms that have been present for the same two 
week period and at least one of the symptoms has to be depressed mood or anhedonia.1  The 
other presenting symptoms may be significant weight loss or weight gain (>5% of body weight 
per month), insomnia or hypersomnia, psychomotor agitation, fatigue or loss of energy, feelings 
of worthlessness or excessive guilt, decreased concentration or indecisive, and recurrent thoughts 
of death or suicidal ideation.1 These symptoms also have to cause impairment in social or 
occupational areas and cannot be attributed to drugs (medical or street), bereavement, or not 
better explained by other psychotic disorders.1,7,8,9 
 Major depression is a common condition affects approximately 14.8 million or 6.7% of 
the American population.2  An estimated 121 million people worldwide are currently affected by 
a form of depression and MDD is the 4th leading cause of disability worldwide.2  In the United 
States, the annual cost related to MDD in 2010 was $210.5 billion dollars.3  The latest statistics 
show in 2007-2010 there were 8 million visits per year for major depressive disorder.4  There is a 
higher incidence in women than men and MDD is a common comorbidity in patients with 
chronic medical conditions (arthritis, DM, heart disease, etc.).5  Major depression may affect all 
ages, races, and the incidence increases with age for both genders.5   The etiology for MDD is 
thought to be multifactorial, arising from genetic factors (neurotransmitter dysfunction), 
developmental (personality issues, childhood events), and psychosocial stress (divorce, 
unemployment, etc.).5 Some of the major neurotransmitter contributors to MDD are thought to 
be serotonin (5-HT), epinephrine, norepinephrine, and dopamine.5,7,8,9  This is why the 
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medications that are given to treat MDD attempt to achieve balance amongst the 
neurotransmitters that regulate our overall mood.   
 Psychotherapy is recommended for patients who suffer from major depressive disorder.  
This is a key component to treatment because it allows for a continuous assessment of suicide 
risk in this population.5 Psychotherapy is also aided with pharmacotherapy treatment.  The drugs 
used pharmacotherapy treatment usually takes 3-6 week before the patient notices a positive 
affect from the medications.5 The first line treatment in patients with MDD are selective 
serotonin reuptake inhibitors (SSRIs), followed by selective norepinephrine reuptake inhibitors 
(SNRIs), or other drug classes that may alter brain neurotransmitter activity.5 If patients fail 
pharmacological therapy they may be candidates for electroconvulsive therapy or phototherapy. 5  
 The pharmacological treatments listed above all play an important part in management 
for MDD however; these medications may not be tolerated or therapeutic to all patients.  The 
U.S. Food and Drug Administration (FDA) approved Brintellix in 2013 for the management of 
major depressive disorder.6 Brintellix is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-
HT1B receptor partial agonist, 5-HT1A receptor agonist and an inhibitor of the 5-HT 
transporters.7,8,9  The areas of the brain that Brintellix affects is designed  to enhance 
neurotransmitter activity, which results in antidepressant activity.   Since this drug works in the 
central nervous system (CNS) it is important to examine if patients are able to tolerate the CNS 
adverse effects associated with Brintellix.  The RCT’s demonstrated that there is increased CNS 
side effects, most common being nausea, but majority of patients are able to tolerate the 
medication and follow through with management.7,8,9 
Objective 
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 The Incidence of nausea is influenced by Brintellix in patients over the age of 18 with 
Major Depressive Disorder (MDD). 
Method 
 The criteria used for the 3 RCT studies included patients over 18, diagnosed with MDD, 
who met the baseline total score on Montgomery-Asberg Depression Rating Scale (MADRS) on the 
first visit.  Patients who were eligible for the study were randomized equally to one of the treatment 
groups and were instructed to take their medication at the same time each day.  The placebo capsule was 
identical to Brintellix capsule.  Some variations did exist between the three studies.  In the study by 
Alverez et al. 5mg Brintellix was compared to placebo for six weeks.7 in the study by Boulenger et al. 
5mg Brintellix was compared to placebo for eight weeks.8 In the trial by Mahableshwarkar et al. 15mg 
Brintellix was compared to placebo for eight weeks.9 The outcomes measured in the three studies 
included the incidence of nausea in patients who are taking Brintellix for MDD. 
 Clinical experts who received rater training and received their rating training certificated were 
allowed to rate patients.7,8,9  These experts followed up with the eligible patients to examine the efficacy 
and tolerability of the medication.  When patients reported to the clinical experts, the patients were asked 
non-leading questions, such as, “how do you feel”?  All adverse events were either observed by the 
clinical expert or reported directly by the patient. 
 A detailed search using Cochrane Systematic Reviews and PubMed databases were completed by 
using the keywords “Vortioxetine”, Major Depression, “Brintellix” with English language being used in 
all studies. The three RCTs were published between 2011 -2013 and located in PubMed database.  
Articles were selected based on their relevance to clinical practice and importance to patient-oriented 
outcomes.  Inclusion criteria consisted of articles that were either RCTs or Primary studies which were up 
to date with no other systematic review, meta-analysis, or review article found on the Cochrane database 
answering the same questions.  Studies excluded were those with patients treated with other 
antidepressant drugs, current psychiatric disorder other than MDD, current or past history of manic or 
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hypomanic episodes, schizophrenia, or any other psychotic features, or received electroconvulsive therapy 
within the last six months. A summary of statistics reported or used were CEA, EER, RRI, ARI, NNH, 
and P-values.  Table 1 displays the demographics and characteristics of these articles. 
Table 1 – Demographics & Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Alvarez7 
(2011) 
RCT 213 18-65 Patients with 
MDD presenting 
with current 
major depressive 
episodes 
according to 
DSM-IV-TR 
criteria were 
included if there 
were an 
outpatient of 
either sex,  
MADRS total 
score >30 
Current 
psychiatric 
disorder other 
than MDD, 
Current or past 
history of 
manic or 
hypomanic 
episodes, 
schizophrenia, 
or any other 
psychotic 
features 
28 Brintellix 5 mg 
VS. Placebo 
assessing adverse 
reactions at each 
visit for 6 weeks, 
starting at 
baseline. During 
visits patients 
were asked non-
leading questions. 
Boulenger8 
(2013) 
RCT 151 18-75 Primary 
diagnosis of 
MDD according 
to DSM-IV-TR 
criteria, a current 
major depressive 
episode (MDE) 
of greater than 3 
month’s duration 
with a MADRS 
score of ≥ 26. 
Current 
psychiatric 
disorder other 
than MDD as 
defined by 
DSM-IV-TR or 
a current or past 
history of a 
manic or 
hypomanic 
episode, 
schizophrenia 
or any other 
psychotic 
features 
34 Brintellix 15 mg 
VS. Placebo 
assessing adverse 
reactions at each 
visit for 8 weeks, 
starting at 
baseline. During 
visits patients 
were asked non-
leading questions. 
Mahables-
hwarkar9 
(2013) 
RCT 153 18-75 Primary 
diagnosis of 
major depressive 
disorder 
(according to 
DSM-IV-TR for 
at least 3 months 
who scores ≥ 22 
on MADRS. 
History of 
psychosis, 
substance 
abuse, 
neurological 
disorders, on a 
medication, risk 
of suicide, 
resistant to 2 
adequate anti-
depressant 
31 Brintellix 5mg 
VS placebo 
assessing adverse 
reactions at the 
end of 8 week 
trial, comparing 
to baseline. 
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treatments for 
at least 6 weeks 
or received 
electro- 
convulsive 
therapy within 
6 months 
 
Outcome Measured 
 
 The outcomes measured were patient oriented evidence that matters (POEMs), relating to 
increased incidence of nausea in patients taking Brintellix for MDD.  The patients in the study 
had to meet with the clinical expert as scheduled times.  During this time the clinical expert 
asked non-leading questions such as, how do you feel?7,8,9  Nausea was reported by the patient or 
observed by the clinical expert then added to adverse events and analyzed by using the Fischer 
exact test.  
Results 
 
 The three studies chosen evaluated for the incidence of nausea in patients 18 and older 
taking Brintellix for MDD.7,8,9  All patients included in each study were assessed prior to 
eligibility  and assessed through the study at prescribed intervals.  All the studies compared 
Brintellix to a placebo group, but varied in duration of study or dosage of Brintellix given.  
During the duration of the study adverse events were recorded, with nausea being the most 
common adverse event.7,8,9  
 In the study conducted by Alvarez et al.7 (2011) analyzed if the incidence of nausea is 
increased in patients taking 5mg of Brintellix (n=108; 38 male 70 female) compared to the 
placebo (n=105; 36 male 69 female).  The study design was a randomized, double blind, placebo 
controlled trial for a six week duration.   In the experimental and control there were male/female 
18 years and older with a diagnosis of MDD.  Refer to Table 1 for inclusion and exclusion 
criteria.  Incidence of nausea was assessed after the completion of each week until the study was 
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finished. After the completion of the study patients were tapered off for two weeks.  The 
experimental and control group both received the placebo for two weeks and then reported for a 
safety follow-up 4 weeks after the completion of the study.   It was reported that 18 (4 to adverse 
events) patients withdrew from the control group and 10 (3 to adverse events) patients withdrew 
from the experimental group.  Patient withdrawal in either group due to nausea was 0. 10 (9.5%) 
patients in the control group and 32 (29.6%) patients in the experiential group reported nausea. 
Patients taking 5mg of Brintellix had a 2.12 times higher risk of experiencing nausea as those 
taking control.  Patients taking 5mg of Brintellix had a 20.1% absolute increase in experiencing 
nausea. For every 4 MDD patients taking 5mg Brintellix, 1 patient would also experience 
nausea, compared to control.  At the end of the study there was a significant (p<0.001) increase 
in nausea in experimental group compared to control group (Table 2). 
 In the study conducted by Boulenger et al8 (2013) analyzed if the incidence of nausea is 
increased in patients taking 15mg of Brintellix (n=151; 54 male 97 female) compared to the 
placebo (n=158; 48 male 110 female).  The study design was a randomized, double blind, 
placebo controlled trial for 8 weeks.  In the experimental and control group there were 
male/female 18 years and older with a diagnosis of MDD. Refer to Table 1 for inclusion and 
exclusion criteria.  Incidence of nausea was assessed weekly for the first 2 weeks and then every 
2 weeks till the end of the study.  After the completion of the study, experimental and control 
were tapered off for 2 weeks with placebo and followed up on 4th week for safety measures.  It 
was reported that 25 (7 to adverse events) patients withdrew from control group and 34 (10 to 
adverse events) patients withdrew from experimental group.  The leading adverse event that 
leads for withdrawal was nausea in the experimental group.  The study did not specify the 
leading cause of withdrawal in control group.  16 (10.1%) patients in the control group and 40 
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(26.5%) in the experimental group reported nausea.  Patients taking 15mg of Brintellix had a 
2.15 higher risk of experiencing nausea as those taking control.  Patients taking 15 mg of 
Brintellix had a 21.7% absolute increase in experiencing nausea.  For every 4 MDD patients 
taking 15mg Brintellix, 1 additional patient would also experience nausea, compared to control.  
At the end of the study there was a significant (p<0.001) increase in nausea in experimental 
group compared to control group (Table 2). 
 In the study conducted by Mahableshwarkar et al.9 (2011) analyzed if the incidence of 
nausea is increased in patients taking 5mg of Brintellix (n=122; 60 male/93 female) compared to 
the placebo group (n=120; 47 male/106 female). The study design was a randomized, double 
blind, placebo controlled trial for 8 weeks.  In the experimental and control group there were 
male and female 18 years and older with a diagnosis of MDD.  Refer to Table 1 for inclusion and 
exclusion criteria.  Incidence of nausea was assessed at weeks 1,2,4,6, and 8.  Control and 
experimental group were both given a placebo taper for 1 week following the study.  Safety 
follow up was done over the phone, 4 weeks after the study.  It was reported that 33 (7 to adverse 
events) participants withdrew from the placebo group and 31 (12 to adverse events) withdrew 
from experiential group. The study did not specify if adverse events relating to nausea was a 
cause of withdraw.  16 (10.6%) patients in the control group and 44 patients in the experimental 
group reported nausea.  Patients taking 5mg of Brintellix had a 1.72 higher risk of experiencing 
nausea as those taking control. Patients taking 5mg of Brintellix had an 18.2% absolute increase 
in experiencing nausea.  For every 5 MDD patients 18 years and older taking 5mg Brintellix, 1 
additional patient would also experience nausea, compared to control.  At the end of the study 
there was a significant (p<0.05) increase in nausea in experimental group compared to control 
group (Table 2). 
Eyler | Brintellix & Nausea | 10 
 
 
 
Table 2 - Incidence of Nausea is Influenced by Brintellix (Vortioxetine) in Patients Over the 
Age of 18 with Major Depressive Disorder (MDD) 
 
Study Control 
event 
rate 
(CER) 
Experimental 
event rate 
(EER) 
Dosage/ EER 
Relative 
risk 
increase 
(RRI) 
Absolute 
risk 
increase 
(ARI) 
Number 
needed 
to harm 
(NNH) 
P-value Statistically 
Significant 
Alvarez et al.7 9.5% 5mg/29.6% 212% 20.1% 4 P<0.001 Yes 
Boulenger et al.8 10.1% 15mg/31.8% 215% 21.7% 4 P<0.001 Yes 
Mahableshwarkar 
et al.9 
10.6% 5mg/28.8% 172% 18.2% 5 P<0.05 Yes 
 
Discussion  
  
 Major Depressive Disorder is a serious condition that may manifest itself in a variety of 
ways.  Treatment for MDD is difficult due to the fact that a variety of variables contribute to this 
condition. Using pharmacological therapy to attempt to balance the CNS neurotransmitters has 
been shown to be an effective treatment for MDD.  When choosing a medication for any 
condition it is important to weigh the advantages vs the disadvantages of a medication.  For 
example, a medication may be effective for desired outcome but the adverse effect(s) of the 
medication may also be harmful. Therefore it is important for a patient to pick a medication that 
is effective and tolerable than a medication that will treat a symptom but replace it with another.  
These decisions are even more important for patients who have to take a medication for the rest 
of their life. 
 Brintellix is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial 
agonist, 5-HT1A receptor agonist and an inhibitor of the 5-HT transporters.7,8,9  Brintellix was 
approved for the treatment of MDD on September 30, 2013 and is considered a multimodal 
antidepressant because it works in multiple ways in the CNS.6  Brintellix is available in 5mg, 10 
mg, 15mg, and 20mg tablets and cost for 1 month supply ranges from $300-350$.10  However, 
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with the availability of cost reduction cards and insurance, many patients pay $50-$100 per 
month.11  This medication is used to treat major depressive disorder and has a black box warning 
with increased suicide in children, young adults, and adults > 65 years old. The only indication 
for the use of Brintellix is major depressive disorder. 6,10  
 Patients with MDD are known to have a high relapse rate and often are found taking 
antidepressants for the duration of their life.5 The three RCTs found that Brintellix was an 
effective treatment for MDD in patients over 18 years old but the focus of this study was to 
analyze the impact of nausea due to Brintellix therapy.7,8,9  Nausea was reported as the most 
common adverse event during the trails.7,8,9  Even though nausea was the number one adverse 
event the studies reported that they were mild cases.7,8,9  So the severity of nausea was low.  
Therefore, even though Brintellix was significant for increasing incidence of nausea, due to the 
low severity of nausea, Brintellix was well tolerated by the patients.   
 Similar limitations existed in all the following studies.  In the three RCTs nausea was 
reported by participant or observed by the clinical expert during follow up.  Nausea is a symptom 
that may arise from a variety of reasons such as, diet, exercise, emotional stress, motion sickness, 
etc. Therefore it may be difficult to decipher if nausea was contributed by lifestyle factors or 
primarily from the experimental arm.  The study did not include this variable as a possibility 
which would result in false positives.  Due to this limitation, there needs to be a more valid 
procedure in recording the influence of nausea due to Brintellix. 
Conclusion 
 
 The systematic review of three randomized controlled trails comparing Brintellix to a 
control group concluded that Brintellix was influential in increasing the incidence of nausea in 
patients over 18 with major depressive disorder.  Variability of major depressive disorder 
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medications is important because these mediations affect the CNS which may contribute to 
undesirable adverse reactions.  With more pharmacological options available helps increases the 
opportunity for management of MDD.  Future studies should include extra guideline with 
reporting incidence of nausea, allowing for clinical reporters to decipher if nausea is due to 
lifestyle factors or Brintellix. 
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